Top Qs
Timeline
Chat
Perspective
Buparvaquone
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Buparvaquone is a naphthoquinone antiprotozoal drug related to atovaquone. It is a promising compound for the therapy and prophylaxis of all forms of theileriosis. Buparvaquone has been shown to have anti-leishmanial activity in vitro. It can be used to treat bovine East Coast fever protozoa in vitro, along with the only other substance known – Peganum harmala.[citation needed] It is the only really effective commercial therapeutic product against bovine theileriosis, where it has been used since the late 1980s.[citation needed]
Remove ads
Remove ads
Industrial production
It was first produced in Great Britain, then in Germany.[citation needed] Its patent expired in the mid-2000s, and was then produced in different countries such as India and Iran.[citation needed]
Use in bovine theileriosis
Using a single dose of 2.5 mg/kg, the recovery rate of curable cases is 90 to 98%. In tropical theileriosis, a dosage of 2.0 mg/kg has the same efficacy. Body temperature returns to normal in two to five days. Parasitemia lowers from 12% on day 0 to 5% the next day, then to 1% by day 5 and none at day 7.[1]
Viruses
Buparvaquone has been shown to inhibit completely vaccinia virus in cell based assay in human cell line.[2]
Molecular target
Buparvaquone resistance appears to be associated with parasite mutations in the Qo quinone-binding site of mitochondrial cytochrome b.[3] Its mode of action is thus likely to be similar to that of the antimalarial drug atovaquone, a similar 2-hydroxy-1,4-naphthoquinone that binds to the Qo site of cytochrome b thus inhibiting Coenzyme Q – cytochrome c reductase.[citation needed]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads